SMT

Surat, India Founded: 1998 • Age: 28 yrs Listed
SMT is recognized as a developer of cardiovascular medical devices.

About SMT

SMT is a publicly listed company based in Surat (India) founded in 1998. SMT is recognized as a developer of cardiovascular medical devices. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 1,090 employees. SMT has completed 2 acquisitions, including Vascular Concepts and Zarek. SMT was last valued at $329.92 million in January 2023. Its chief executive, as recorded, is Bhargav Kotadia. Its website smtpl.com draws about 13 thousand monthly visits. Its Indian entity Sahajanand Medical Technologies Limited reported revenue of β‚Ή1,219 Cr. SMT offers products and services including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit. Its focus areas include Medical Devices and Cardiovascular Devices.

Company details

SMT, officially known as Sahajanand Medical Technologies Ltd., is engaged in the development and manufacturing of minimally invasive cardiovascular devices. The company operates within the healthcare sector, focusing on coronary stents, structural heart devices, and peripheral intervention solutions. Products such as Supraflex Cruz and Hydra Aortic Valve are designed to address conditions like coronary artery disease and aortic stenosis. With a global presence, SMT is committed to advancing patient care through innovative medical solutions across multiple regions.

  • Headquarters Surat, India
  • Employees 1,090
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website smtpl.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Sahajanand Medical Technologies Ltd.
  • Date of Incorporation 18 Oct, 2001
  • Jurisdiction Surat, Gujarat, India
Key Metrics
  • Market Cap
    ₹5,522 Cr

    SMT · NSE

  • Share Price
    ₹550.00

    +1.24% today

  • Revenue
    ₹1,210 Cr

    FY 2025-26 · +15.3% YoY

  • EBITDA
    ₹171 Cr

    Margin 14.1%

  • Net Profit
    ₹65.27 Cr

    FY 2025-26 · +170.2% YoY

  • P/E (TTM)
    82.8x

    P/B 7.8x

  • ROE
    10.9%

    ROCE 11.4%

  • Debt / Equity
    0.44

    Interest cover 25.3x

  • Latest Funding Round
    $20.87M (USD), Unspecified

    Jan 2023

  • Investors
  • Employee Count
    1,090
  • Investments & Acquisitions

Products & Services of SMT

SMT offers a comprehensive portfolio of products and services, including Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.

Supraflex Cruz
Coronary Stents

Advanced coronary stent used for arterial blockages treatment.

Hydra Aortic Valve
Structural Heart Devices

Valve designed for treating severe aortic stenosis conditions.

Cocoon Septal Occluder
Occluders

Device used to close atrial septal heart defects.

Renofit
Peripheral Intervention Devices

Balloon expandable stent for renal and biliary issues.

Apps and channels of SMT

its YouTube channel SMT has 528 subscribers and 30 videos.

SMT
YouTube 528 subscribers 30 videos Science & Technology
Open channel

Videos from SMT

The most watched videos on SMT's YouTube channel, SMT (528 subscribers). Click a video to play it here.

Dr, Bharat Dalvi. JJ Hospital, Mumbai.
3.8K views
🫀 TAVR Implantation Techniques: Tailoring Success for Each Self-Expanding TAVR Platform 🫀
1.1K views
Contemporary best clinical practice for TAVI
1K views
Live case: PFO closure transmission from Hammersmith Hospital, London
923 views

More on SMT.

Funding Insights of SMT

  • Total Rounds 4
  • Last Round Unspecified β€” $20.87M
  • First Round $35,130

    (Mar 2009)

  • Investors Count 79

All 4 funding rounds of SMT with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2023$20.87MUnspecified$329.92MKotak Mahindra Bank
–
Jan 2022$11.09MUnspecified$309.22MSBI Mutual Fund
Dec 2016$25.22MUnspecified–Samara Capital
–
Mar 2009$35,130Unspecified$β€’β€’β€’β€’β€’Rahul Gaywala
Valuation history
DateValuationStage
Jan 2023$329.92Mβ€’β€’β€’β€’β€’β€’β€’β€’
Jan 2022$309.22Mβ€’β€’β€’β€’β€’β€’β€’β€’
Mar 2009$β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’
Premium access

Full valuation and stage history of SMT

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $329.92M (Jan 2023). 79 investors in total: 4 institutional and 75 angel.

Investors in SMT

SMT has secured backing from 79 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include SBI Mutual Fund, Kotak Mahindra Bank and Plutus.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
Private equity investments are managed across multiple sectors.
samaracapital.comMumbai, India
Commercial banking services are offered to corporate and retail customers.
1985kotak.comMumbai, India
Provides mutual funds management and financial advisory services.
1987sbimf.comMumbai, India
Financial planning and investment management services are provided by Plutus.
plutuswealth.comLondon, United Kingdom

Madhuri Madhusudan Kela

unknown_75cab185e2a04d0e8

Martin B Leon

unknown_3bcdec058a924c94b

Debojyoti Dutta

unknown_117f06fafcf64a569

Sriram Nadathar

unknown_b5262fdc2b2547d48

Alka Manoj Rabadiya

unknown_2039a3a702834e328

Ashit Kumar Sanghrajka

unknown_e253a2306b5a40048
Premium access

Investor details for SMT

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Sahajanand Medical Technologies Limited (SMT)

Sahajanand Medical Technologies Limited is the primary company behind SMT. The board of Sahajanand Medical Technologies Limited currently have 8 directors; the longest-serving is Dhirajlal Vallabhbhai Kotadia, appointed in 2004. 27 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Dhirajlal Vallabhbhai Kotadia
DIN 00013035
Director25 Mar 200422 yrs 7 moSahajanand Medical Technologies Limited
Bhargav Dhirajlal Kotadia
DIN 06575042
Managing Director06 May 201313 yrs 6 moSahajanand Medical Technologies Limited
Abhishek Rajendrakumar Kabra
DIN 06782685
Director28 Dec 20169 yrs 10 moSahajanand Medical Technologies Limited
Jose Calle Gordo
DIN 08568779
Director20 Sep 20197 yrs 1 moSahajanand Medical Technologies Limited
Sonalika Dhar
DIN 10221436
Director30 Jun 20233 yrs 4 moSahajanand Medical Technologies Limited
Debasis Panigrahi
DIN 08838872
Director22 Sep 20233 yrs 1 moSahajanand Medical Technologies Limited
Harvinder Pal Singh
DIN 10416949
Director01 Jul 20251 yr 4 moSahajanand Medical Technologies Limited
Priyanka Dhirajlal Cohen
DIN 11181810
Director03 Jul 20251 yr 4 moSahajanand Medical Technologies Limited

People of SMT

3 people are tracked at SMT (3 in leadership); the tracked headcount is 1,090.

NameRoleGroup
CEO & MDLeadership
Chief Executive OfficerLeadership
Gaurav Goel
CCOLeadership
Premium access

Complete people profiles for SMT

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of SMT

SMT is a publicly listed company on the NSE with ticker symbol SMT in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: SMT
  • Listed entitySahajanand Medical Technologies Limited

Financials of SMT

Exchange-reported figures of Sahajanand Medical Technologies Limited, the listed company behind SMT (NSE: SMT).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹1,210 Cr
+15.3% YoY
EBITDA
₹171 Cr
+51.0% YoY
Profit After Tax
₹65.27 Cr
+170.2% YoY
Net Worth
₹695 Cr
+22.9% YoY
Total Assets
₹1,019 Cr
+19.2% YoY
Total Debt
₹306 Cr
+20.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2021-22FY 2020-21
Income statement
Revenue1,2101,050954690589
Revenue growth+15.3%+10.0%-+17.2%-
EBITDA17111311032.397.06
EBITDA margin+14.1%+10.8%+11.5%+4.7%+1.2%
Profit before tax80.2840.8133.09(30.38)(45.29)
Net profit65.2724.16(12.83)(47.95)(49.01)
Net profit margin+5.4%+2.3%-1.3%-7.0%-8.3%
EPS (β‚Ή)6.482.09(1.31)(5.49)(8.14)
Balance sheet
Total assets1,019855774826685
Net worth695566540401334
Total debt306254201386325
Cash & bank75.4910273.53174144
Net working capital518456396460405
Cash flow
Cash from operations10573.5241.1016.8446.35
Cash from investing(120)(50.44)(41.80)(154)(169)
Cash from financing(12.04)5.7713.13109212
ParticularsSep 2026Jun 2026Sep 2025Jun 2025
Revenue373352299281
Revenue growth (YoY)+24.7%+25.2%--
Other income2.242.672.343.16
EBITDA65.5548.5847.9731.63
EBITDA margin+17.6%+13.8%+16.0%+11.3%
Depreciation20.9120.4117.2216.17
Interest6.816.556.015.78
Profit before tax40.0724.2927.0812.84
Tax13.609.206.18(4.91)
Net profit26.4715.0920.9017.75
EPS (β‚Ή)2.561.451.940.00
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue551530509457439403
Revenue growth+3.9%+4.2%+11.2%+4.1%+9.1%-
EBITDA77.9216.0521.1256.8424.5822.91
EBITDA margin+14.1%+3.0%+4.2%+12.4%+5.6%+5.7%
Profit before tax46.05(3.29)(3.86)34.1712.6215.22
Net profit42.34(2.19)(35.08)20.70(6.60)(13.27)
Net profit margin+7.7%-0.4%-6.9%+4.5%-1.5%-3.3%
EPS (β‚Ή)4.43(0.81)(3.54)2.13(0.10)(1.16)
Balance sheet
Total assets891802725732592462
Net worth677622631688534430
Total debt21117590.3840.6849.6226.63
Cash & bank6.4736.4112.248.2211932.69
Net working capital195152132183318219
Cash flow
Cash from operations8.4311.7725.6274.5334.02105
Cash from investing(52.25)(50.77)(57.92)(198)(91.01)(55.66)
Cash from financing13.9963.1531.2794.7082.96(55.09)
ParticularsSep 2026Jun 2026Sep 2025Jun 2025
Revenue159153135123
Revenue growth (YoY)+17.5%+24.2%--
Other income1.951.401.731.70
Total expenses138133112115
EBITDA20.4020.5123.408.17
EBITDA margin+12.9%+13.4%+17.3%+6.6%
Depreciation5.074.745.084.62
Interest4.234.164.673.79
Profit before tax13.0513.0115.381.46
Tax3.223.693.18(8.15)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsSep 2026Jun 2026Sep 2025Jun 2025
Revenue373352299281
Revenue growth (YoY)+24.7%+25.2%--
Other income2.242.672.343.16
EBITDA65.5548.5847.9731.63
EBITDA margin+17.6%+13.8%+16.0%+11.3%
Depreciation20.9120.4117.2216.17
Interest6.816.556.015.78
Profit before tax40.0724.2927.0812.84
Tax13.609.206.18(4.91)
Net profit26.4715.0920.9017.75
EPS (β‚Ή)2.561.451.940.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2021-22FY 2020-21
Revenue1,2101,050954690589
Revenue growth+15.3%+10.0%-+17.2%-
Other income8.2211.086.99(2.79)3.44
Total expenses1,040937844657581
Employee cost0.00292254193136
EBITDA17111311032.397.06
EBITDA margin+14.1%+10.8%+11.5%+4.7%+1.2%
Depreciation74.1662.5364.5037.7435.42
Interest24.4320.7319.4422.2420.37
Profit before tax80.2840.8133.09(30.38)(45.29)
Tax11.2115.6640.4518.4127.05
Net profit65.2724.16(12.83)(47.95)(49.01)
Net profit margin+5.4%+2.3%-1.3%-7.0%-8.3%
EPS (β‚Ή)6.482.09(1.31)(5.49)(8.14)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2021-22FY 2020-21
Equity & liabilities
Share capital9.819.779.759.248.89
Reserves & surplus686556530392325
Shareholders' funds (net worth)695566540401334
Minority interest6.8324.7426.2318.0212.93
Secured loans244182161368278
Unsecured loans62.2771.3839.6217.6947.35
Total debt306254201386325
Total liabilities1,019855774826685
Assets
Gross block672540498290263
Net block343288296207203
Capital work in progress9.016.3113.4412259.81
Investments58.554.926.300.000.00
Inventories309267252160143
Sundry debtors286263215236255
Cash & bank balances75.4910273.53174144
Loans & advances10261.6249.1462.3124.82
Total current assets773694590633567
Total current liabilities255238194173162
Net working capital518456396460405
Total assets1,019855774826685
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2021-22FY 2020-21
Opening cash10171.6759.2411222.99
Net cash from operating activities10573.5241.1016.8446.35
Net cash from investing activities(120)(50.44)(41.80)(154)(169)
Net cash from financing activities(12.04)5.7713.13109212
Net change in cash(26.43)28.8512.43(28.69)89.08
Closing cash75.4910273.53174144
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2021-22FY 2020-21
Growth
Sales growth+15.3%+10.0%-+17.2%-
EBITDA growth+51.0%+2.7%-+358.8%-
PBT growth+96.8%+23.3%+9998.0%+32.9%+9997.0%
Net income growth+170.2%+288.3%-+2.2%-
Revenue CAGR (3Y)+20.6%+20.3%---
EBITDA CAGR (3Y)+74.0%+152.0%---
Profitability & leverage
Net income margin+5.7%+2.5%-0.8%-7.1%-12.3%
Return on capital employed+11.4%+9.8%+7.2%+1.1%+2.9%
Return on net worth+11.0%+5.2%-1.3%-12.5%-13.0%
Debt / equity0.440.410.320.970.56
Long-term debt / equity0.100.100.150.790.36
Interest cover25.3241.1042.69-415.70-71.83
Efficiency & per share
Fixed asset turnover2.001.972.032.492.97
Inventory turnover4.203.954.194.554.55
Debtors turnover4.404.284.372.812.44
EPS (β‚Ή)6.652.09(1.31)(5.49)(8.14)
Dividend per share (β‚Ή)0.000.000.000.000.00
Book value per share (β‚Ή)70.8757.9655.4243.4237.52
ParticularsSep 2026Jun 2026Sep 2025Jun 2025
Revenue159153135123
Revenue growth (YoY)+17.5%+24.2%--
Other income1.951.401.731.70
Total expenses138133112115
EBITDA20.4020.5123.408.17
EBITDA margin+12.9%+13.4%+17.3%+6.6%
Depreciation5.074.745.084.62
Interest4.234.164.673.79
Profit before tax13.0513.0115.381.46
Tax3.223.693.18(8.15)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue551530509457439403
Revenue growth+3.9%+4.2%+11.2%+4.1%+9.1%-
Other income6.067.534.1212.566.6711.75
Total expenses473514488401415380
Employee cost15114113211011070.76
EBITDA77.9216.0521.1256.8424.5822.91
EBITDA margin+14.1%+3.0%+4.2%+12.4%+5.6%+5.7%
Depreciation21.1916.5020.6017.5113.1812.79
Interest16.7410.378.5017.725.456.65
Profit before tax46.05(3.29)(3.86)34.1712.6215.22
Tax2.554.6230.5913.4513.5325.56
Net profit42.34(2.19)(35.08)20.70(6.60)(13.27)
Net profit margin+7.7%-0.4%-6.9%+4.5%-1.5%-3.3%
EPS (β‚Ή)4.43(0.81)(3.54)2.13(0.10)(1.16)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital9.819.769.759.759.248.89
Reserves & surplus668612621678525421
Shareholders' funds (net worth)677622631688534430
Secured loans20114280.0035.4949.6226.28
Unsecured loans10.7833.1610.385.190.000.35
Total debt21117590.3840.6849.6226.63
Total liabilities891802725732592462
Assets
Gross block18717417712210573.22
Net block91.9493.5899.7463.4259.5739.75
Capital work in progress3.063.701.831.350.005.54
Investments50249845941774.7872.48
Inventories15113913294.8585.6982.09
Sundry debtors117136132171186194
Cash & bank balances6.4736.4112.248.2211932.69
Loans & advances12047.1529.5649.4840.5246.38
Total current assets394358306323431356
Total current liabilities199206174141113137
Net working capital195152132183318219
Total assets891802725732592462
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash36.2512.1013.1336.0310.0615.36
Net cash from operating activities8.4311.7725.6274.5334.02105
Net cash from investing activities(52.25)(50.77)(57.92)(198)(91.01)(55.66)
Net cash from financing activities13.9963.1531.2794.7082.96(55.09)
Net change in cash(29.83)24.15(1.03)(28.66)25.97(5.30)
Closing cash6.4736.4112.248.2211932.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+3.9%+4.2%+11.2%+4.1%+9.1%-
EBITDA growth+385.5%-24.0%-62.8%+131.2%+7.3%-
PBT growth+9998.0%+14.8%-+170.8%-17.1%+9997.0%
Net income growth+2033.3%+93.8%-269.5%+413.6%+50.3%-
Revenue CAGR (3Y)+6.4%+6.5%+8.1%---
EBITDA CAGR (3Y)+11.1%-13.2%-2.7%---
Profitability & leverage
Net income margin+7.9%-1.5%-6.8%+4.5%-0.2%-2.6%
Return on capital employed+7.4%+3.1%+0.6%+7.8%+6.2%+11.5%
Return on net worth+6.7%-0.4%-5.3%+3.4%-1.4%-3.1%
Debt / equity0.300.210.100.070.080.12
Long-term debt / equity0.050.030.010.000.000.00
Interest cover29.51-2,304.441,634.6245.0547.8165.71
Efficiency & per share
Fixed asset turnover3.063.033.404.044.945.55
Inventory turnover3.813.924.495.075.244.81
Debtors turnover4.373.953.362.572.311.90
EPS (β‚Ή)4.43(0.81)(3.54)2.13(0.10)(1.16)
Dividend per share (β‚Ή)0.000.000.000.000.000.00
Book value per share (β‚Ή)69.0263.6964.7170.5857.7948.32

Investments & Acquisitions by SMT

SMT has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Vascular Concepts and Zarek.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Coronary and peripheral stents are manufactured for arterial disease treatments.
vascularconcepts.comHalstead, United Kingdom1992May 2020β€’β€’β€’β€’
zarek.com.br0Oct 2019β€’β€’β€’β€’
Premium access

Complete acquisition details for SMT

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of SMT

6 dated milestones of SMT across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded SMT is founded.
  2. Funding First funding round of $35K.
  3. Milestone Reaches Minicorn status.
  4. Acquisition Acquires Zarek.
  5. Acquisition Acquires Vascular Concepts.
  6. Funding Latest funding round, Unspecified, of $20.9M.

Web traffic of SMT

The website of SMT (smtpl.com) receives about 13.4K visits a month.

  • Monthly visits
    13.4K

    ▼ 37% vs previous month

Similar websites

Websites whose visitors overlap most with SMT. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
myhospitalnow.com
100%
#757,497View details
masterplan-inc.com
92%
View details
aiimspatna.org
aiimspatna.org
92%
–
medicalfair-india.com
91%
#1,842,824View details
emediahealth.com
emediahealth.com
61%
–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 10 similar websites and full traffic analytics for SMT

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 10 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Smt

Premium access

Complete news archive for SMT

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about SMT

SMT was founded in 1998 and raised its 1st funding round 11 years after it was founded.

SMT is headquartered in Surat, India. It is registered at Surat, Gujarat, India.

Bhargav Kotadia is the CEO of SMT, as recorded in our data.

SMT has 1,090 employees.

The primary company behind SMT, Sahajanand Medical Technologies Limited, reported revenue of β‚Ή1,219 Cr for FY 2026, up 18% year on year.

SMT, officially known as Sahajanand Medical Technologies Ltd., is engaged in the development and manufacturing of minimally invasive cardiovascular devices. The company operates within the healthcare sector, focusing on coronary stents, structural heart devices, and peripheral intervention solutions. Products such as Supraflex Cruz and Hydra Aortic Valve are designed to address conditions like coronary artery disease and aortic stenosis. With a global presence, SMT is committed to advancing patient care through innovative medical solutions across multiple regions.

SMT offers Supraflex Cruz, Hydra Aortic Valve, Cocoon Septal Occluder, and Renofit.

Yes, SMT is publicly traded on NSE under the ticker symbol SMT.

SMT has made 2 acquisitions, including Vascular Concepts, and Zarek.

SMT has 79 investors. Key investors include SBI Mutual Fund, Kotak Mahindra Bank, Plutus, Madhuri Madhusudan Kela, and Samara Capital.

The valuation of SMT is $329.92M as of Jan 2023.

SMT operates through Sahajanand Medical Technologies Limited.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available